Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Phase 3

Efficacy and Safety of VER-01 in the Treatment of Participants With Chronic Painful Lumbosacral Radiculopathy

NCT06956014 · tracked via the Priya Life Science USA tracker
Sponsor
Vertanical GmbH
Phase
Phase 3
Started
2026-09-22
Last updated
2026-11-02

Condition(s) studied

Lumbosacral Radiculopathy

Investigational drug(s) / intervention(s)

VER-01Placebo

VER-01: Standardized soft extract from Cannabis sativa DKJ127 L., cannabis flos (Cannabis flower), corresponding to 19 mg Δ9-Tetrahydrocannabinol (THC) per ml drug product

Placebo: Comparator without active ingredient

Study summary

The aim of the trial is to prove the efficacy and safety of VER-01 compared to placebo in patients with chronic painful lumbosacral radiculopathy (PLSR) for whom drug treatment is indicated and previous optimized treatments with non-opioid analgesics have not led to sufficient pain relief or were unsuitable due to contraindications or intolerance.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Participants ≥ 18 years of age, all sexes * Participant voluntarily provided written informed consent * Participant is willing and able to comply with scheduled visits, treatment plan, eDiary, and other trial-related procedures throughout trial participation Exclusion Criteria: * Pregnant or breastfeeding female patients * Known history of previous or current severe psychiatric disorder as per DSM-5 (e.g., schizophrenia, bipolar disorder, severe anxiety disorder, psychotic disorder, post-traumatic stress disorder), or currently taking antipsychotic medication * Cardiovascular event or clinically significant cardiac dysfunction (e.g., congestive heart failure, myocardial ischemia, arrhythmias, poorly controlled high blood pressure, congenital long QT syndrome) within 12 months or a cardiac disorder that, in the opinion of the investigator, would put the patient at risk of a clinically significant arrhythmia or myocardial infarction

Primary outcome measure(s)

  • Efficacy based on pain reduction — From Baseline to Treatment Week 12
    The primary endpoint is the absolute change in mean leg pain intensity in the index leg measured on an 11-point numerical rating scale (NRS) at Treatment Week 12 compared to Baseline.

Trial sites (32)

FacilityCityRegionStatus
AMR Mobile Mobile Alabama Recruiting
Alliance for Multispecialty Research - Tempe I Tempe Arizona Recruiting
Central Medical Research Institute Long Beach California Recruiting
Tekton Research - Longmont Longmont Colorado Recruiting
Bradenton Research Center Bradenton Florida Recruiting
AGA Clinical Trials Hialeah Florida Recruiting
Green Leaf Clinical Trials Jacksonville Florida Recruiting
K2 Medical Research - Maitland II Maitland Florida Recruiting
Floridian Research Institute LLC I Miami Florida Recruiting
Alma Clinical Research Miami Florida Recruiting
Conquest Research - Lake Nona Orlando Florida Recruiting
Alfa Medical Research - Pembroke Pines Pembroke Pines Florida Recruiting
United Medical Research Port Orange Florida Recruiting
Conquest Research - Winter Park Winter Park Florida Recruiting
Alliance for Multispecialty Research - Wichita East Wichita Kansas Recruiting
Elixia Clinical Research Collaborative Springfield Massachusetts Recruiting
Monroe Biomedical Research - Monroe Monroe North Carolina Recruiting
Progressive Medicine of the Triad, LLC Winston-Salem North Carolina Recruiting
Velocity Clinical Research - Cleveland Cleveland Ohio Recruiting
Epic Medical Research - Chickasha Chickasha Oklahoma Recruiting
Velocity Clinical Research - Medford Medford Oregon Recruiting
Clinitiative - Clinical Trials of South Carolina - Charleston Charleston South Carolina Recruiting
Alliance for Multispecialty Research - Knoxville Knoxville Tennessee Recruiting
Central Texas Clinical Research, LLC Austin Texas Recruiting
DFW Clinical Trials Carrollton Texas Recruiting
Innovare Research Group I Friendswood Texas Recruiting
Synergy Groups Medical - Southeast Houston Houston Texas Recruiting
R & H Clinical Research Katy Texas Recruiting
Epic Clinical Research - Lewisville Lewisville Texas Recruiting
Grayline Research Center Wichita Falls Texas Recruiting
Boeson Research Provo Utah Recruiting
CenExel JBR - Salt Lake City Salt Lake City Utah Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06956014 on ClinicalTrials.gov ↗ ← All trials in the USA